MedTrace Logo

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

NCT07369895 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-27

No results posted yet for this study

Summary

This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D

Using the traditional 3+3 dose escalation method.

Sponsors & Collaborators

  • O&D BioTech Group CO., Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-28
Primary Completion
2028-03-28
Completion
2028-03-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07369895 on ClinicalTrials.gov